A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
Monica Archibald,1 Tara Pritchard,1 Hayley Nehoff,1 Rhonda J Rosengren,1 Khaled Greish,1,2 Sebastien Taurin1 1Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand; 2Aljawhara Centre for Molecular Medicine, Arabian Gulf University, Manama, Kingdom of Bahrain Abstract...
Main Authors: | Archibald M, Pritchard T, Nehoff H, Rosengren RJ, Greish K, Taurin S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-01-01
|
Series: | International Journal of Nanomedicine |
Subjects: | |
Online Access: | https://www.dovepress.com/a-combination-of-sorafenib-and-nilotinib-reduces-the-growth-of-castrat-peer-reviewed-article-IJN |
Similar Items
-
Nilotinib-Induced Acute Interstitial Nephritis during the Treatment of Chronic Myeloid Leukemia
by: Min Jeong Kim
Published: (2021-12-01) -
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
by: Emole J, et al.
Published: (2016-02-01) -
Examining the Effects of Dasatinib, Sorafenib, and Nilotinib on Vascular Smooth Muscle Cells: Insights into Proliferation, Migration, and Gene Expression Dynamics
by: Khalid Alhazzani, et al.
Published: (2023-10-01) -
Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib
by: Khaleed J Khaleel, et al.
Published: (2018-01-01) -
Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation
by: Osvaldo Contreras, et al.
Published: (2018-02-01)